Clinical Trial Detail

NCT ID NCT01797120
Title Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors PrECOG, LLC.
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus + Fulvestrant

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST